Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.56 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 7/20 | 0.51 |
| ▸ | HTR7 | P34969 | 5/20 | 0.51 |
| ▸ | SLC9A1 | P19634 | 5/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7823537 | 0.98 | KMO (0.55) | KMOASIC3PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL7825287 | 0.85 | SLC9A1 (0.49) | ASIC3HTR2BHTR7SLC9A1 | |
| SCHEMBL9392947 | 0.85 | SLC9A1 (0.59) | HTR2BHTR7SLC9A1 | |
| SCHEMBL27400137 | 0.85 | SLC9A1 (0.55) | SLC9A1 | |
| SCHEMBL7827609 | 0.85 | SLC9A1 (0.55) | SLC9A1 | |
| Hydrochloric Acid SCHEMBL7825292 | 0.84 | SIRT2 (0.49) | ASIC3HTR2BHTR7SLC9A1 | |
| Hydrochloric Acid SCHEMBL7830653 | 0.83 | SLC9A1 (0.58) | DHODHHTR2BHTR7SLC9A1 | |
| Hydrochloric Acid SCHEMBL7816188 | 0.83 | SLC9A1 (0.58) | HTR2BHTR7SLC9A1 | |
| SCHEMBL8802133 | 0.83 | SLC9A1 (0.51) | DHODHHTR2BHTR7SLC9A1 | |
| SCHEMBL5441718 | 0.83 | SLC9A1 (0.53) | HTR2BHTR7SLC9A1DRD2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-H08511243-A | — | — | 1996-11-26 | — | — | JP | claimed |
| CN-1123545-A | Guanidine derivatives as inhibitors of Na+/H+ exchange in cells | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-05-29 | — | — | CN | claimed |
| EP-0699185-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-03-06 | — | — | EP | claimed |
| WO-1994026709-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-24 | — | — | WO | claimed |
| EP-1097141-B1 | IMIDAZOLE DERIVATIVES WITH BIPHENYLSULFONYL SUBSTITUTION, METHOD FOR PREPARING THEM AND THEIR USE AS A DRUG OR DIAGNOSTIC AGENT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-05-23 | — | — | EP | disclosed |
| EP-1076651-B1 | SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| EP-1097140-B1 | BIPHENYLSULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS A DRUG OR DIAGNOSTIC AGENT AND DRUG CONTAINING THEM | AVENTIS PHARMA GMBH (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-6573288-B1 | Compounds are inhibitors of the sodium-dependent bicarbonate/chloride ion exchanger which can be used as medicines for the prophylaxis or treatment of a wide range of diseases, for example the treatment and/or prophylaxis of | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-06-03 | — | — | US | disclosed |
| US-6486189-B2 | TREATMENT OR PROPHYLAXIS OF AN ILLNESS CAUSED BY AN ISCHEMIC CONDITION, OR FOR THE TREATMENT OF IMPAIRED RESPIRATORY DRIVE | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-11-26 | — | — | US | disclosed |
| EP-1053224-B1 | BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT | AVENTIS PHARMA GMBH (DE) | 2002-08-21 | — | — | EP | disclosed |
| US-20020045761-A1 | Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them | KLEEMANN HEINZ-WERNER (DE) | 2002-04-18 | — | — | US | disclosed |
| US-6372917-B1 | INHIBIT CELLULAR SODIUM ION-DEPENDENT CHLORIDE ION/BICARBONATE-EXCHANGE MECHANISM OR SODIUM/BICARBONATE SYMPORTER; TREATMENT OF ALL ACUTE OR CHRONIC DAMAGE CAUSED BY ISCHEMIA OR ILLNESSES INDUCED THEREBY | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-16 | — | — | US | disclosed |
| WO-1999057102-A1 | SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-11-11 | — | — | WO | disclosed |
| US-5968978-A | ANTIARRYTHMIA AGENTS, ANTIISCHEMIC AGENTS, INHIBIT PROLIFERATION OF CELLS | HOECHST MARION ROUSSEL DEUTSCHLAND (DE) | 1999-10-19 | — | — | US | disclosed |
| WO-1999040064-A1 | BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-08-12 | — | — | WO | disclosed |
| EP-0903339-A2 | Biphenylsulfonylcyanamides, process for their preparation and their use as medicaments | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-03-24 | — | — | EP | disclosed |
| EP-0855392-A2 | Five-membered heterocycles having biphenylsulphonyl substituents, processes for the preparation thereof, their use as medicaments or diagnostic agent and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-29 | — | — | EP | disclosed |
| EP-0726254-B1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS (JP) | 1998-05-06 | — | — | EP | disclosed |
| US-5731350-A | Substituted benzenedicarboxylic acid diguanides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-03-24 | — | — | US | disclosed |
| EP-0774457-A1 | Substituted benzodicarboxylic acid diguanidines, process for their preparation, and their use as medicament or diagnostic agent | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045761-A1 | Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them | BAX, BCL2, TNNI3 | KMO 1828/4885ASIC3 3700/4885PRSS1 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.